Compare Colgate-Palmolive Company (CL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs Sana Biotechnology Inc — how do they compare? Colgate-Palmolive Company trades at $92.43 (market cap $73.59B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Colgate-Palmolive Company is far larger — about 65.1× Sana Biotechnology Inc's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| CL | SANA | |
|---|---|---|
Market Cap | $73.59B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $5.92 |
52-Week Low | $74.98 | $2.68 |
Enterprise Value | $80.07B | $1.05B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $92.54, down 0.65% on the day, with neutral technical signals and strong fundamentals. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% revenue growth and margin expansion. Recent news highlights director share sales and mixed regional performance, particularly weakness in North America despite global strength.
CL offers stable dividend returns and consistent earnings but faces valuation concerns with a P/E of 36.34 and competitive pressures in key markets. Analyst consensus targets $99.10 with 42% buy ratings, suggesting moderate upside potential balanced against premium valuation and domestic market challenges.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
